Comparative Pharmacology
Head-to-head clinical analysis: PHENURONE versus ZONISAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENURONE versus ZONISAMIDE.
PHENURONE vs ZONISAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Anticonvulsant; blocks voltage-gated sodium channels and T-type calcium channels, reducing neuronal excitability and seizure propagation. Also weakly inhibits carbonic anhydrase.
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
Oral, initial 100 mg daily, may increase by 100 mg every 2 weeks; maintenance 200-400 mg daily in 1-2 divided doses; maximum 600 mg daily.
None Documented
None Documented
Clinical Note
moderateZonisamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Fluconazole
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Terminal half-life approximately 60-70 hours (range 50-80 hours) in adults; at steady state, half-life may be slightly longer. Clinical context: requires 2-3 weeks to achieve steady state.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Renal: approximately 30% unchanged; remainder as glucuronide conjugate and reduced metabolite. Biliary/fecal: minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Zonisamide."